Literature DB >> 22173119

HPV analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma.

Justin A Bishop1, Takenori Ogawa, Xiaofei Chang, Peter B Illei, Edward Gabrielson, Sara I Pai, William H Westra.   

Abstract

For patients with head and neck squamous cell carcinoma (HNSqCC), the development of squamous cell carcinoma (SqCC) in the lung may signal a new primary or the onset of metastatic dissemination. Although the distinction influences prognosis and therapy, it may not be straightforward on histologic or clinical grounds. The human papillomavirus (HPV) is an etiologic agent for SqCCs arising from the oropharynx but not for SqCCs arising from other head and neck sites. For patients with HNSqCC who develop a lung SqCC, HPV analysis could be useful in establishing tumor relationships. High-risk HPV in situ hybridization was performed on 54 lung SqCCs from patients with a previously diagnosed HNSqCC and on 166 primary lung carcinomas from patients without a prior HNSqCC. HPV was detected in 11 of 220 (5%) cases. All HPV-positive cases were from patients with a prior oropharyngeal SqCC. For the paired oropharyngeal and lung SqCCs, HPV status was concordant in 95% of cases. Time from treatment of HPV-positive oropharyngeal carcinomas to detection of lung carcinoma ranged from 1 to 97 months (mean, 36 mo). Two HPV-positive cancers were detected in the lung 8 years after treatment of the oropharyngeal primary. Despite the long interval, E6 sequencing analysis of 1 of these paired samples confirmed that the tumors harbored the same HPV-16 variant. HPV does not seem to play a role in the development of primary lung cancer. For patients with oropharyngeal SqCC who develop lung SqCC, HPV analysis may be helpful in clarifying tumor relationships. These relationships may not be obvious on clinical grounds, as HPV-related HNSqCC may metastasize long after treatment of the primary tumor.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22173119      PMCID: PMC3273906          DOI: 10.1097/PAS.0b013e3182395c7b

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  43 in total

1.  [Point mutation of p53 and detection of human papillomavirus DNA in bronchogenic carcinoma].

Authors:  X Zhang; Y Zhu; L Li
Journal:  Zhonghua Nei Ke Za Zhi       Date:  1995-10

2.  Bronchopulmonary changes after laryngeal cancer treatment--differentiation between metastatic laryngeal and second primary cancer.

Authors:  T Rott; B Luzar; J Sorli
Journal:  Acta Otolaryngol Suppl       Date:  1997

3.  Second neoplasm in patients with head and neck cancer.

Authors:  X León; M Quer; S Diez; C Orús; A López-Pousa; J Burgués
Journal:  Head Neck       Date:  1999-05       Impact factor: 3.147

4.  Human papillomavirus type 16 sequence variants: identification by E6 and L1 lineage-specific hybridization.

Authors:  C M Wheeler; T Yamada; A Hildesheim; S A Jenison
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

5.  [Annual chest X-ray in patients after treatment for laryngeal or oral cancer: only a limited number of second primary lung cancers detected].

Authors:  J Buwalda; C L Zuur; H Lubsen; J G Tijssen; R Koole; G J Hordijk
Journal:  Ned Tijdschr Geneeskd       Date:  1999-07-17

6.  Detection of human papillomavirus in squamous cell carcinomas of the lung by polymerase chain reaction.

Authors:  T Bohlmeyer; T N Le; A L Shroyer; N Markham; K R Shroyer
Journal:  Am J Respir Cell Mol Biol       Date:  1998-02       Impact factor: 6.914

7.  [The role of oncogenic human papillomaviruses in tonsillar squamous cell carcinomas with functional inactivation of the retinoblastoma protein].

Authors:  M Helbig; T Andl; T Kahn; W Klein-Kühne; C Conradt; A Dietz; F X Bosch
Journal:  HNO       Date:  1999-09       Impact factor: 1.284

8.  High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma.

Authors:  A L Reed; J Califano; P Cairns; W H Westra; R M Jones; W Koch; S Ahrendt; Y Eby; D Sewell; H Nawroz; J Bartek; D Sidransky
Journal:  Cancer Res       Date:  1996-08-15       Impact factor: 12.701

9.  Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression.

Authors:  V G Gorgoulis; P Zacharatos; A Kotsinas; T Liloglou; A Kyroudi; M Veslemes; A Rassidakis; T D Halazonetis; J K Field; C Kittas
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

10.  Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma.

Authors:  P P Leong; B Rezai; W M Koch; A Reed; D Eisele; D J Lee; D Sidransky; J Jen; W H Westra
Journal:  J Natl Cancer Inst       Date:  1998-07-01       Impact factor: 13.506

View more
  16 in total

1.  Metastatic HPV-Associated Oropharyngeal Versus Primary Pulmonary Squamous Cell Carcinoma: is p16 Immunostain Useful?

Authors:  Jefree J Schulte; Jamie Steinmetz; Larissa V Furtado; Aliya N Husain; Mark W Lingen; Nicole A Cipriani
Journal:  Head Neck Pathol       Date:  2020-04-29

Review 2.  Human Papillomavirus Laboratory Testing: the Changing Paradigm.

Authors:  Eileen M Burd
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

3.  Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma.

Authors:  Carole Fakhry; Qiang Zhang; Phuc Felix Nguyen-Tan; David Rosenthal; Adel El-Naggar; Adam S Garden; Denis Soulieres; Andy Trotti; Vilija Avizonis; John Andrew Ridge; Jonathan Harris; Quynh-Thu Le; Maura Gillison
Journal:  J Clin Oncol       Date:  2014-06-23       Impact factor: 44.544

4.  Surgical salvage improves overall survival for patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer.

Authors:  Theresa Guo; Jesse R Qualliotine; Patrick K Ha; Joseph A Califano; Young Kim; John R Saunders; Ray G Blanco; Gypsyamber D'Souza; Zhe Zhang; Christine H Chung; Ana Kiess; Christine G Gourin; Wayne Koch; Jeremy D Richmon; Nishant Agrawal; David W Eisele; Carole Fakhry
Journal:  Cancer       Date:  2015-03-17       Impact factor: 6.860

5.  Use of p40 and p63 immunohistochemistry and human papillomavirus testing as ancillary tools for the recognition of head and neck sarcomatoid carcinoma and its distinction from benign and malignant mesenchymal processes.

Authors:  Justin A Bishop; Elizabeth A Montgomery; William H Westra
Journal:  Am J Surg Pathol       Date:  2014-02       Impact factor: 6.394

6.  An Algorithm to Evaluate Suspected Lung Metastases in Patients with HPV-Associated Oropharyngeal Cancer.

Authors:  Kyle K VanKoevering; Emily Marchiano; Heather M Walline; Thomas E Carey; Jonathan B McHugh; J Chad Brenner; Christine M Goudsmit; Emily Belille; Matthew E Spector; Andrew G Shuman
Journal:  Otolaryngol Head Neck Surg       Date:  2017-09-26       Impact factor: 3.497

Review 7.  The morphologic profile of HPV-related head and neck squamous carcinoma: implications for diagnosis, prognosis, and clinical management.

Authors:  William H Westra
Journal:  Head Neck Pathol       Date:  2012-07-03

8.  The Fidelity of p16 Staining as a Surrogate Marker of Human Papillomavirus Status in Fine-Needle Aspirates and Core Biopsies of Neck Node Metastases: Implications for HPV Testing Protocols.

Authors:  Brittany J Holmes; Zahra Maleki; William H Westra
Journal:  Acta Cytol       Date:  2015-03-10       Impact factor: 2.319

9.  Detection of human papillomavirus (HPV) in clinical samples: evolving methods and strategies for the accurate determination of HPV status of head and neck carcinomas.

Authors:  William H Westra
Journal:  Oral Oncol       Date:  2014-06-02       Impact factor: 5.337

10.  Metastatic squamous cell carcinoma to the brain: an unrecognized pattern of distant spread in patients with HPV-related head and neck cancer.

Authors:  J Ruzevick; A Olivi; W H Westra
Journal:  J Neurooncol       Date:  2013-02-14       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.